ANN ARBOR, Mich., Feb. 6 /PRNewswire/ -- QuatRx Pharmaceuticals Company announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by QuatRx.
The underwriters of the offering will be Banc of America Securities LLC, as sole book-running manager, SG Cowen & Co., as co-lead manager, and Lazard Capital Markets and Pacific Growth Equities, LLC as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Banc of America Securities LLC, Prospectus Department, 100 West 33rd Street, New York, New York 10001, (646) 733-4166.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About QuatRx
QuatRx is a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. QuatRx, founded in 2000, is headquartered in Ann Arbor, Michigan and has operations in Europe through Hormos Medical Ltd., a wholly owned subsidiary located in Turku, Finland.
Source: QuatRx Pharmaceuticals Company
